Gelone Steven P.

About Gelone Steven P.

Steven Gelone, Pharm.D., is a biopharmaceutical executive with a long track record in clinical development, preclinical development, and drug development strategy. His most notable affiliation is with Nabriva Therapeutics plc, where he served as President and Chief Operating Officer beginning July 24, 2018, and later joined the board of directors effective March 10, 2021. Prior to that, he held a series of senior leadership roles within Nabriva and its Austrian predecessor, including Chief Development Officer, Head of Business Development, and Chief Scientific Officer. That internal progression indicates deep familiarity with the company’s pipeline, operations, and anti-infective focus. He joined Nabriva in 2014. Before Nabriva, Dr. Gelone built experience across several biotechnology and pharmaceutical organizations. He served as Head of Clinical Research and Development at Spark Therapeutics in 2014, and spent nearly a decade at ViroPharma as Vice President of Clinical and Preclinical Development from 2005 to 2014. He also held roles as Director of Medical Affairs at Vicuron Pharmaceuticals and Director of Clinical Pharmacology and Experimental Medicine at GlaxoSmithKline Pharmaceuticals. Taken together, these positions point to broad expertise across the drug development continuum, from early-stage research through clinical execution and late-stage planning. Academically, he earned both a B.S. Pharm. and a Pharm.D. from Temple University in Philadelphia. At Nabriva, his remit included development leadership, operational oversight, and support for commercialization efforts. Public sources do not attribute a single landmark decision directly to him, so it is prudent to stay generic on that point. Still, the record consistently presents him as a seasoned executive who helped guide Nabriva’s development organization and contributed to the company’s broader strategy in anti-infective therapeutics.